Company intelligence / Profile preview
Genelux Corporation
- Ownership
- Public · GNLX
- Development stage
- Phase 3
Overview
Genelux’s lead candidate Olvi‐Vec has shown positive topline results in the Phase II VIRO‐15 trial for heavily pretreated patients with platinum-resistant or refractory ovarian cancer. The data demonstrated independent anti-tumor activity and reversal of platinum resistance in the tumor microenvironment. Over more than a decade of clinical studies (>150 patients), Olvi‐Vec has been generally well tolerated with evidence of clinical benefit[5].
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic viruses (specifically, modified vaccinia virus)Immunotherapy[1][5]
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $82.3M
- Total revenue
- $8K
- Enterprise value
- $66.1M
Beyond the preview
Go deeper on Genelux Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genelux Corporation.